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Abstract: Hemophilic arthropathy (HA) typically begins with proliferative synovitis that shares
some similarities with inflammatory arthritides, in which the proinflammatory cytokine tumor
necrosis factor (TNF)-α has a crucial pathogenetic role. Inappropriate release of TNF-α was shown
to contribute to arthropathy development following intra-articular bleeding in hemophilic mice.
Here, we were interested in determining whether systemic levels of TNF-α and synovial tissue
expression of the TNF-α/TNF receptor (TNF-R) system could be increased and related to joint
damage in hemophilia A patients with severe HA. Serum levels of TNF-α measured by quantitative
enzyme-linked immunosorbent assay (ELISA) were significantly increased in HA patients (n = 67)
compared to healthy controls (n = 20). In HA patients, elevated TNF-α levels were significantly
associated with the number of hemarthroses, the grade of synovial hypertrophy, and both the
clinical World Federation of Hemophilia score and ultrasound score. The expression of TNF-α,
TNF-R1, and TNF-R2 was strongly increased in HA synovium (n = 10) compared to the non-inflamed
osteoarthritis control synovium (n = 8), as assessed by both immunohistochemistry and Western
blotting. Increased protein levels of TNF-α, TNF-R1, and TNF-R2 were retained in vitro by HA
fibroblast-like synoviocytes (n = 6) with respect to osteoarthritis control fibroblast-like synoviocytes
(n = 6). Stimulation with TNF-α resulted in a significant increase in HA fibroblast-like synoviocyte
proliferation quantified by the water-soluble tetrazolium (WST)-1 assay, while it had no relevant effect
on osteoarthritis fibroblast-like synoviocytes. Quantification of active/cleaved caspase-3 by ELISA
demonstrated that TNF-α did not induce apoptosis either in HA or in osteoarthritis fibroblast-like
synoviocytes. The TNF-α/TNF-R system may represent a crucial mediator of proliferative synovitis
and, therefore, a new attractive target for the prevention and treatment of joint damage in HA patients.
Our findings provide the groundwork for further clinical investigation of anti-TNF-α therapeutic
feasibility in hemophiliacs.
Keywords: hemophilic arthropathy; TNF-α; TNF receptors; fibroblast-like synoviocytes; proliferative
synovitis
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1. Introduction
Intra-articular bleeding plays a pivotal role in the pathogenesis of hemophilic arthropathy (HA),
a major clinical manifestation of hemophilia characterized by large-joint synovitis evolving into
articular cartilage destruction and subchondral bone resorption that frequently results in osteopenia
or osteoporosis [1–7]. HA shows a tendency to be more severe in hemophilia A than in hemophilia
B and, depending on the frequency of bleeding episodes and the severity of the related symptoms,
may have a devastating impact on the patient’s quality of life [1,8]. Indeed, notwithstanding recent
advances in the management of acute bleeds and the optimization of prophylactic factor replacement
protocols, HA remains a major burden for hemophilia patients [8–10]. Therefore, a deeper deciphering
of the pathogenetic mechanisms that underlie HA-related progressive joint damage and that, hopefully,
may become novel targets for therapeutic purposes still represents a major unmet need in this
area [8,9,11,12]. In HA patients, recurring bleeds into the joint cavity with tissue hemosiderin
deposition are proposed to elicit synovial inflammation and hyperplasia similar to those found in
inflammatory arthritides [3,4,8,9,13]. In fact, iron-laden synovial tissue produces various inflammatory
cytokines promoting the proliferation of fibroblast-like synoviocytes, which are considered key players
of joint inflammation and destruction through the aggressive invasion of the extracellular matrix and
production of proinflammatory mediators and cartilage-degrading enzymes [3,4,8,9]. Studies on animal
models have recently helped to shed some light on the underlying pathobiology driving hemarthrosis
toward HA [14,15]. A rapid in vivo proinflammatory response characterized by both local and systemic
innate inflammatory mediators has been demonstrated following acute hemarthrosis in hemophilic
rats [14]. In particular, gene expression analysis revealed increased synovial fluid levels of multiple
proinflammatory mediators, such as interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α, while
plasma analysis demonstrated significantly increased systemic levels of IL-6 [14]. Another recent
study focusing on the detailed mapping of the early HA pathogenesis through a time-course study of
induced hemarthrosis in hemophilic rats revealed proliferative synovitis dominated by neutrophil
and macrophage infiltration that develops within hours after hemarthrosis [15]. Strikingly, articular
cartilage and subchondral bone degeneration appeared to be early and parallel events, suggesting that
these processes are also caused by a direct effect of blood exposure and cannot simply be considered
consequences of inflammation [15].
The proinflammatory cytokine TNF-α has been extensively implicated in the pathogenesis of
proliferative synovitis and bone resorption and is a major target for the treatment of inflammatory
arthritis, such as rheumatoid arthritis (RA) [16–18]. Of note, a very recent experimental study has
suggested that a crucial pathomechanism of inflammatory arthritis, namely the inappropriate release
of TNF-α by the TNF-α convertase (TACE; also known as ADAM17) and its regulator, iRhom2, may
have a pivotal role also in mediating HA in hemophilic FVIII-deficient mice [19]. Indeed, it was
demonstrated that blood and its components are capable of activating the iRhom2/ADAM17-dependent
release of TNF-α from macrophages [19]. Moreover, the induction of hemarthrosis led to increased
levels of TNF-α in the affected joints of FVIII-deficient mice, and the inactivation of TNF-α or iRhom2
reduced synovial inflammation and osteopenia in this mouse model for HA [19]. As far as human HA
is concerned, to our knowledge, the TNF-α/TNF receptor (TNF-R) system has not been specifically
investigated apart from two former studies reporting increased levels of TNF-α in supernatants of
cultured hemosiderotic synovial tissue from hemophilia patients [20,21]. Since the aforementioned
data indicate that abnormal TNF-α release may represent a potential new target to prevent bone
resorption following a joint bleed in mice, we aimed at determining whether systemic levels of TNF-α
and synovial tissue expression of this proinflammatory cytokine and its receptors could be increased
and related to the development of proliferative synovitis in hemophilia A patients with severe HA.
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2. Materials and Methods
2.1. Patients
Sixty-seven hemophilia A patients attending the Center for Bleeding Disorders of the Careggi
University Hospital in Florence, Italy, were consecutively enrolled in the study. All patients had
suffered from at least one joint bleeding. Clinicodemographic characteristics and imaging findings of
the study population are shown in Table 1. All patients gave informed consent, and the study was
conducted in agreement with the Declaration of Helsinki and approved by the institutional review
board at the Careggi University Hospital, Florence, Italy (study code no. 996, 27/12/2006).
Table 1. Clinical characteristics and imaging findings of 67 hemophilia A patients.
Clinical characteristics/Imaging Findings Patients
Median age (range), years 36.3 (16–69)
Primary and secondary prophylaxis treatment, n (%) 8 (12.0%)
Tertiary prophylaxis treatment, n (%) 22 (32.8%)
On demand treatment, n (%) 37 (55.2%)
Viral infections, n (%)
HCV-RNA 29 (43.3%)
Anti-HCV 43 (64.2%)





Synovial hypertrophy, n (%)
≤2.5 mm 40 (59.7%)
>2.5 mm 27 (40.3%)
Clinical WFH score, mean ± SD 37.6 ± 21.2
Radiographic Pettersson score, mean ± SD 8.46 ± 7.62




WFH: World Federation of Hemophilia; US: ultrasound. * All HIV positive with undetectable viremia (HIV-RNA
< 20 cp/mL) and receiving antiretroviral therapy.
The median age of patients was 36.3 years (range 16–69 years). All patients (100%) had severe
hemophilia A (FVIII:C <1 IU/dL). Thirty-seven out of 67 patients (55.2%) were treated on demand,
eight of 67 (12.0%) with primary and secondary prophylaxis, and twenty-two of 67 (32.8%) with
tertiary prophylaxis. According to the last guidelines for the management of hemophilia of the World
Federation of Hemophilia (WFH) [22], primary prophylaxis treatment started before the second large
joint bleed and at the age of three years in the absence of osteochondral joint disease, documented by
physical examination and imaging studies. Secondary prophylaxis started after two or more bleedings
into large joints and before the onset of joint disease documented by physical examination and imaging
studies [22]. Tertiary prophylaxis instead is when treatment started in the presence of documented joint
disease. As far as viral infections are concerned, all patients were screened for HCV-RNA, anti-HCV,
and HIV positivity (Table 1).
2.2. Clinical and Imaging Score
The severity of HA was measured using the WFH orthopedic joint scale score consisting of a
physical examination and pain scale (referred to as the clinical WFH score) [23]. All patients were
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studied by knee X-ray and ultrasound (US). X-ray score (radiographic Pettersson score) evaluates
osteoporosis, enlarged epiphysis, irregular subchondral bone surface, narrowing of the joint space,
subchondral cyst formation, erosions of the joint margins, the gross incongruence of articulating bone
ends, and deformity (angulation and displacement between the articulating bones) [24]. The X-ray
score for a single joint varies between 0 (normal joint) and 13 (i.e., a totally destroyed joint). Knee US
was performed by an experienced sonographer (DM, unaware of the severity of the clinical history),
and US findings were scored according to the already published criteria (US score range 0–21 for
a single joint with a cut-off less than 5) [25–27]. Patients were divided into three groups according
to the total number of hemarthroses in their life: (1) patients with less than 10 hemarthroses (<10);
(2) patients with hemarthroses 10–50 (10–50); and (3) patients with hemarthroses greater than 50 (>50)
(Table 1) [26].
2.3. Serum TNF-αMeasurements
Fresh peripheral venous blood from 67 HA patients and 20 healthy controls (median age 37.1 years,
range 18–62 years) was drawn, allowed to clot for 30 min before centrifugation at 1500× g for 15 min.
Serum samples were collected and stored in aliquots at −80 ◦C until used. Serum levels of TNF-α were
measured with a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human
TNF-alpha Quantikine HS ELISA; catalog no. HSTA00E; R&D Systems, Minneapolis, MN, USA),
following the manufacturer’s protocol. Optical density was measured by a microtitre plate reader at
450 nm. The serum levels of TNF-αwere read off from a standard curve according to the manufacturer’s
instructions. The detection range and the sensitivity of the assay were 0.2–10 pg/mL and 0.049 pg/mL,
respectively. Each sample was measured in duplicate. The inter-assay and intra-assay variances
were <10%.
2.4. Synovial Biopsy Samples
Synovial tissue samples were obtained from 10 HA patients with severe knee arthropathy (median
age 38.2 years, range 25–66 years; all treated on demand) who underwent arthroplasty during surgery
as described elsewhere [28]. Synovial samples from eight male patients with degenerative knee
osteoarthritis (OA) (median age 54.7 years, range 37–75 years) who underwent total joint replacement
were used as controls [28]. Each synovial specimen was divided into different parts. One part was cut
into small pieces, fixed in 10% buffered formalin and, after standard processing, embedded in paraffin
wax and used for routine histopathological and immunohistochemical analyses. Another part was
immediately frozen in liquid nitrogen for protein extraction and Western blotting analysis. The last
part of the synovial tissue was used for the isolation of fibroblast-like synoviocytes.
2.5. Cell Isolation and Culture
Fibroblast-like synoviocytes were successfully isolated from 6 HA and 6 OA control synovial
biopsy specimens subjected to a mild proteolytic treatment with 0.05% trypsin and 0.5 mM EDTA
in phosphate-buffered saline for 10 min at 37 ◦C under gentle shaking as described elsewhere [29].
Trypsin was then neutralized with fetal calf serum (FCS) (Celbio, Milan, Italy) and cells were plated
in culture dishes in RPMI 1640 medium (Cambrex Bio Science, Milan, Italy) supplemented with 15%
FCS, 2 mM glutamine and penicillin-streptomycin (Cambrex Bio Science). The cells were considered
fibroblast-like synoviocytes (type B synoviocytes) if negative on immunostaining with anti-CD68,
anti-CD14, anti-CD11b, and anti-CD11c antibodies (markers of type A macrophage-like synoviocytes),
positive by staining for the enzyme uridine diphosphoglucose dehydrogenase and if they had a
spindle-shaped, fibroblast-like morphology (>95% cell purity). HA and OA fibroblast-like synoviocyte
monolayers were used within the seventh passage in culture.
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2.6. Immunohistochemistry
Synovial tissue sections (5 µm thick) were deparaffinized, rehydrated, boiled for 10 min
in sodium citrate buffer (10 mM, pH 6.0) for antigen retrieval and subsequently treated with
3% H2O2 in methanol for 15 min to block endogenous peroxidase activity and subjected to
immunoperoxidase-based immunohistochemistry using the ready-to-use UltraVision™ Large Volume
Detection System Anti-Polyvalent, HRP kit (catalog no. TP-125-HL; Lab Vision, Fremont, CA, USA).
After blocking non-specific antibody binding sites, tissue sections were incubated overnight at 4 ◦C
with the following primary antibodies: rabbit polyclonal anti-TNF-α (1:100; catalog no. ab6671; Abcam,
Cambridge, UK), rabbit polyclonal anti-TNF receptor 1 (TNF-R1) (1:500; catalog no. ab19139; Abcam)
and rabbit polyclonal anti-TNF receptor 2 (TNF-R2) (1:50; catalog no. ab15563; Abcam). Isotype-
and concentration-matched irrelevant rabbit IgG (Sigma-Aldrich, St. Louis, MO, USA) were used as
negative controls. The day after, tissue slides were incubated sequentially with biotinylated secondary
antibodies and streptavidin-peroxidase solution (both from Lab Vision) followed by immunoreactivity
development using 3,3′-diaminobenzidine tetrahydrochloride (DAB; catalog no. SK-4100; Vector
Laboratories, Burlingame, CA, USA) or ImmPACT VIP (catalog no. SK-4605; Vector Laboratories)
peroxidase substrates as chromogens. Immunostained tissue sections were examined with a Leica
DM4000 B microscope equipped with a Leica DFC310 FX 1.4-megapixel digital color camera and the
Leica software application suite LAS V3.8 (Leica Microsystems, Mannheim, Germany).
2.7. Western Blotting
Proteins were extracted from synovial specimens by homogenization for 5 min in ice-cold lysis
buffer [50 mM Tris HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.25% sodium dodecyl
sulfate (SDS)] supplemented with the protease inhibitor cocktail (Complete; Roche, Mannheim,
Germany), followed by sonication. Proteins were also extracted from cultured fibroblast-like
synoviocytes at basal conditions or after treatment for 24 h with recombinant human TNF-α (10 ng/mL;
PeproTech, Rocky Hill, NJ, USA). Protein lysates were cleared by centrifugation for 30 min at 4 ◦C at
15000 rpm and assayed for protein content using Bradford’s method. Fifty micrograms of proteins were
electrophoresed in SDS 12%–13.5% polyacrylamide gel under reducing conditions and then blotted to
a nitrocellulose transfer membrane (Amersham Biosciences, Piscataway, NJ, USA). The membranes
were blocked in 5% non-fat dry milk with 0.05% Tween-20 in phosphate buffered saline for 1 h
at room temperature, and then incubated overnight at 4 ◦C with the following rabbit polyclonal
antibodies: anti-TNF-α, anti-TNF-R1, and anti-TNF-R2 (all 1:1000; Abcam). After incubation with
horseradish peroxidase-conjugated anti-rabbit IgG (Cell Signaling Technology, Beverly, MA, USA) for
1 h at room temperature, immune complexes were detected with the enhanced chemiluminescence
detection system and the membranes were exposed to autoradiographic films (Amersham Biosciences).
The membranes were stripped and reprobed with rabbit monoclonal anti-α-tubulin antibodies (1:1000;
catalog no. #2144; Cell Signaling Technology) as the loading control. Densitometric analysis of the
bands was performed using the free-share ImageJ software 64-bit Java 1.8.0_112 Windows version
(NIH, Bethesda, Maryland, USA; online at http://rsbweb.nih.gov/ij) and the values were normalized
to α-tubulin.
2.8. Cell Viability Assay
HA and OA fibroblast-like synoviocytes were seeded onto 96-well plates (40 × 103 cells per well)
in RPMI 1640 with 15% FCS and were left to adhere overnight. Cells were then washed three times with
serum-free medium and incubated in RPMI 1640 with 0.2% FCS for an additional 24 h. Fibroblast-like
synoviocytes were incubated for 24 h in RPMI 1640 with 0.2% FCS containing 10 ng/mL recombinant
human TNF-α (PeproTech). Cell viability was determined by a cell proliferation assay using the
water-soluble tetrazolium (WST)-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene
disulfonate) reagent (Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s
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protocol. All measurements were performed in triplicate, and the results were expressed as the
percentage increase/decrease in cell viability over the basal response.
2.9. Active Caspase-3 Assay
HA and OA fibroblast-like synoviocytes were plated in culture dishes at a concentration of
1–1.5 × 106 per dish in RPMI 1640 with 15% FCS. Once at 70% confluence, fibroblast-like synoviocytes
were washed three times with serum-free medium and incubated in RPMI 1640 with 0.2% FCS
for 24 h. Fibroblast-like synoviocytes were then incubated for 24 h in RPMI 1640 with 0.2% FCS
containing 10 ng/mL recombinant human TNF-α (PeproTech). Positive apoptosis controls were
obtained by incubation of cells with staurosporine (Sigma-Aldrich). Cleaved (active) caspase-3 levels in
fibroblast-like synoviocyte lysates were determined with a specific quantitative colorimetric sandwich
ELISA kit designed to specifically detect human active caspase-3 protein (Invitrogen, Carlsbad, CA,
USA). Fibroblast-like synoviocytes were collected, centrifuged, and then the pellet was incubated in
ice-cold cell extraction buffer for 30 min and treated according to the manufacturer’s instructions.
All measurements were performed in triplicate.
2.10. Statistical Analysis
Statistical analyses were performed using the SPSS software for Windows, version 25.0 (Statistical
Package for Social Sciences Inc., Chicago, IL, USA). Data are expressed as the mean ± standard error of
the mean (SEM) or median and interquartile range (IQR), as appropriate. Student’s t-test was used to
compare two independent groups for normally distributed parameters, while the Mann–Whitney U-test
was used to compare two independent groups for non-normally distributed parameters. Spearman’s
rank correlation coefficient (ρ) was used to analyze the relationship between two continuous variables.
Values of p < 0.05 were considered statistically significant.
3. Results
3.1. Circulating Levels of TNF-α Are Raised and Correlate with Joint Disease Severity in HA Patients
TNF-α was measured in serum samples from HA patients and healthy controls by quantitative
sandwich ELISA. Serum levels of TNF-αwere significantly increased in HA patients (median 2.9 pg/mL,
IQR 2.6–3.3 pg/mL) compared to healthy controls (median 1.0 pg/mL, IQR 0.4–1.5 pg/mL) (p < 0.0001)
(Figure 1A). No significant differences in serum TNF-α levels were detected according to the HCV-RNA,
anti-HCV, or HIV status of HA patients.
When HA patients were stratified according to the total number of hemarthroses in their
life, there were no differences in TNF-α serum levels between the group with <10 and the group
with 10–50 episodes of hemarthrosis (n = 7 patients and n = 17 patients, respectively). Therefore,
these patients were grouped (n = 24 patients) for further comparison with the group with >50 episodes
of hemarthrosis (n = 43 patients). Circulating levels of TNF-α in the >50 group (median 3.2 pg/mL,
IQR 2.9–3.6 pg/mL) were significantly higher than in the <10/10–50 groups (median 2.6 pg/mL, IQR
2.5–2.9 pg/mL) (p < 0.0001) (Figure 1B). As far as synovial hypertrophy is concerned, TNF-α levels
were significantly elevated in HA patients with the synovial thickness of >2.5 mm (median 3.2 pg/mL,
IQR 2.9–3.5 pg/mL) compared to patients with the synovial thickness of ≤2.5 mm (median 2.8 pg/mL,
IQR 2.5–3.1 pg/mL) (p = 0.002) (Figure 1C). Furthermore, serum TNF-α levels were significantly greater
in HA patients with US score ≥5 (median 3.1 pg/mL, IQR 2.7–3.3 pg/mL) than in those with US score
<5 (median 2.6 pg/mL, IQR 2.5–2.9 pg/mL) (p = 0.02) (Figure 1D).
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Figure 1. Increased circulating levels of tumor necrosis factor (TNF)-α in hemophilic arthropathy 
(HA). Serum concentrations of TNF-α were determined by colorimetric sandwich enzyme-linked 
immunosorbent assay in 67 patients with HA and 20 healthy controls. (A) Serum TNF-α levels in total 
HA patients and controls. (B–D) Serum TNF-α levels in HA patients stratified according to the 
number of hemarthroses (B), synovial hypertrophy (C), and ultrasound (US) score values (D). Boxes 
show 25th and 75th percentiles. Vertical lines below and above boxes show 10th and 90th percentiles. 
Lines inside the boxes represent the medians, circles the outliers, and asterisks the extreme values. 
Significant differences between groups are indicated. Mann–Whitney U-test was used for statistical 
analysis. 
In HA patients, a significant positive correlation between the circulating levels of TNF-α and 
both clinical WFH score (ρ = 0.61, p < 0.0001) and US score (ρ = 0.28, p = 0.02) was found (Figure 2A,B). 
Moreover, we observed a trend toward a positive correlation between circulating TNF-α and 
radiographic Pettersson score, though this analysis did not reach statistical significance (ρ = 0.15, p = 
0.058). 
Figure 1. Increased circulating levels of tumor necrosis factor (TNF)-α in hemophilic arthropathy
(HA). Serum concentrations of TNF-α were determined by colorimetric sandwich enzyme-linked
immunosorbent assay in 67 patients with HA and 20 healthy controls. (A) Serum TNF-α levels in total
HA patients and controls. (B–D) Serum TNF-α levels in HA patients stratified according to the number
of hemarthroses (B), synovial hypertrophy (C), and ultrasound (US) score values (D). Boxes show 25th
and 75th percentiles. Vertical lines below and above boxes show 10th and 90th percentiles. Lines inside
the boxes represent the medians, circles the outliers, and asterisks the extreme values. Significant
differences between groups are indicated. Mann–Whitney U-test was used for statistical analysis.
I HA patients, a significant positive correlation between the circulating levels of TNF-α
and both clinical WFH score (ρ = 0.61, p < 0.0001) and US score (ρ = 0.28, p = 0.02) was found
(Figure 2A,B). Moreover, we observed a trend toward a positive correlation between circulating TNF-α
and radiographic Pettersson score, though this analysis did not reach statistical significance (ρ = 0.15,
p = 0.058).
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inflamed OA control synovial specimens, particularly in synoviocytes, the vascular endothelium, and 
perivascular cells (Figure 3A). As displayed in Figure 3B, the analysis of protein levels in tissue 
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Figure 2. Circulating tu or necrosis factor (T F)-α levels positively correlate ith clinical orld
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arthropathy. Correlation of serum TNF-α levels with clinical WFH score (A) and US score (B). Data are
shown as scatterplots, each dot representing a patient. Spearman’s rank correlation coefficient (ρ) and p
values are indicated.
3.2. The Expression of TNF-α, TNF-R1, and TNF-R2 Is Strongly Increased in HA Synovial Tissue and
Cultured HA Fibroblast-Like Synoviocytes
The ex vivo expression of TNF-α, TNF-R1, and TNF-R2 in knee synovial tissue sections from HA
patients and OA controls was investigated by immunoperoxidase-based immunohistochemical staining
procedures. TNF-α, TNF-R1, and TNF-R2 immunostainings were strongly increased either in the
hyperplastic synovial lining layer or the synovial sublining layer of HA compared to non-inflamed OA
control synovial specimens, particularly in synoviocytes, the vascular endothelium, and perivascular
cells (Figure 3A). As displayed in Figure 3B, the analysis of protein levels in tissue homogenates by
Western blotting confirmed that the expression of TNF-α, TNF-R1, and TNF-R2 was significantly
increased in HA synovium compared with OA control synovium (p < 0.05 for all comparisons).
J. Clin. Med. 2019, 8, 939 9 of 14
J. Clin. Med. 2019, 8, 939 9 of 14 
 
 
Figure 3. Expression of tumor necrosis factor (TNF)-α, TNF receptor 1 (TNF-R1), and TNF receptor 2 
(TNF-R2) in synovial tissue from patients with hemophilic arthropathy (HA) and osteoarthritis (OA). 
(A) Representative microphotographs of tissue sections subjected to immunoperoxidase-based 
immunohistochemical staining for TNF-α (brown color), TNF-R1, and TNF-R2 (purple color) are 
shown. TNF-α, TNF-R1, and TNF-R2 immunostaining is strongly increased either in the hyperplastic 
lining or in the sublining layers of the HA synovium compared to non-inflamed OA control 
synovium. Original magnification: ×10 and ×20. Scale bar: 200 μm (×10 panels), 100 μm (×20 panels). 
(B) Western blotting of total protein extracts from the synovium of HA patients (n = 10) and OA 
controls (n = 8). Representative immunoblots for TNF-α, TNF-R1, and TNF-R2 are shown. The 
densitometric analysis of the bands normalized to α-tubulin is reported in the histograms. Data are 
the mean ± SEM of the optical density in arbitrary units (a.u.). * p < 0.05 vs. OA (Student’s t-test). 
Elevated protein expression levels of TNF-α, TNF-R1, and TNF-R2 were retained in vitro by 
cultured HA fibroblast-like synoviocytes (p < 0.05 vs. OA fibroblast-like synoviocytes for all 
comparisons) (Figure 4A). 
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im uno ist c ic l st i i g for F-α (brown color), TNF-R1, and TNF-R2 (purple c lor) are
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lining or in the sublining layers of the HA synovium compared to non-inflamed OA control synovium.
Original agnification: ×10 and ×20. Scale bar: 200 µm (×10 panels), 100 µm (×20 panels). (B) Western
blotting of total protein extracts from the synovium of HA patients (n = 10) and OA controls (n = 8).
Representative immunoblots for TNF-α, TNF-R1, and TNF-R2 are shown. The densitometric analysis
of the bands normalized to α-tubulin is reported in the histograms. Data are the mean ± SEM of the
optical density in arbitrary units (a.u.). * p < 0.05 vs. OA (Student’s t-test).
Elevate r tei expression levels of TNF-α, TNF-R1, and TNF-R2 were retai ed in vitro
by cultured HA fibroblast-like synoviocytes (p < 0.05 vs. OA fibroblast-like synoviocytes for all
comparisons) (Figure 4A).
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(Student’s t-test). (C) Levels of active (cleaved) caspase-3 in HA-FLS and OA-FLS, as measured by the 
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We evaluated the ability of TNF-α to influence fibroblast-like synoviocyte proliferation by WST-
1 cell viability assay. Stimulation with recombinant human TNF-α (10 ng/mL) resulted in a significant 
increase in the proliferation of HA fibroblast-like synoviocytes (p < 0.05 vs. the basal condition) 
(Figure 4B). Conversely, TNF-α had no relevant effect on proliferation of OA control fibroblast-like 
synoviocytes (Figure 4B). Quantification of active/cleaved caspase-3 levels demonstrated that TNF-α 
did not induce apoptosis either in HA or in OA fibroblast-like synoviocytes (Figure 4C). 
4. Discussion 
This study was undertaken based on the evidence that (i) HA usually begins with proliferative 
synovitis that shares some similarities with inflammatory arthritis in which the TNF-α cytokine is 
recognized as a crucial pathogenetic orchestrator, and (ii) inappropriate release of TNF-α contributes 
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c lt re -FLS and osteoarthritis control FLS (OA-FLS). Representative TNF-α, TNF-R1, and TNF-R2
immunoblots are shown; α-tubulin was used as a loading control. The densitometric analysis of the
bands normalized to α-tubulin is reported in the histograms. Data are mean ± SEM of optical density
in arbitrary units (a.u.). * p < 0.05 vs. OA-FLS (Student’s t-test). (B) Cell viability evaluated at the
basal condition or after treatment with recombinant human TNF-α (10 ng/mL) using the water-soluble
tetrazolium (WST)-1 cell proliferation reagent. Cell viability in response to TNF-α is expressed as the
percentage increase/decrease over the basal response for both HA-FLS and OA-FLS. Bars represent
the mean ± SEM. Results are representative of three independent experiments performed with each
one of the six HA-FLS and six OA-FLS lines. * p < 0.05 vs. the respective basal condition (Student’s
t-test). (C) Levels of active (cleaved) caspase-3 in HA-FLS and OA-FLS, as measured by the specific
enzyme-linked immunosorbent assay on cell lysates. Data are the mean ± SEM of three independent
experiments performed in triplicate with each one of the six HA-FLS and six OA-FLS lines.
3.3. TNF-α Fosters HA Fibroblast-Like Synoviocyte Proliferation
We evaluated the ability of TNF-α t influ nce fib oblast-like synoviocyte proliferation by WST-1
cell viability assay. Stimulation with recombinant human TNF-α (10 ng/mL) resulted in a significant
increase in the proliferation of HA fibroblast-like synoviocytes (p < 0.05 vs. the basal condition)
(Figure 4B). Conversely, TNF-α had no relevant effect on proliferation of OA control fibroblast-like
synoviocytes (Figure 4B). Quantification of active/cleaved caspase-3 levels demonstrated that TNF-α
did not induce apoptosis either in HA or in OA fibroblast-like synoviocytes (Figure 4C).
4. Discussion
This study was undertaken based on the evidence that (i) HA usually begins with proliferative
synovitis that shares some similarities with inflammatory arthritis in which the TNF-α cytokine
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is recognized as a crucial pathogenetic orchestrator, and (ii) inappropriate release of TNF-α
contributes to arthropathy development following intra-articular bleeding in hemophilic FVIII-deficient
mice [3,4,8,9,19]. To investigate whether the TNF-α/TNF-R pathway could contribute to the
pathogenesis of human HA, here we combined ex vivo studies on serum samples and synovial
biopsies and in vitro studies on isolated fibroblast-like synoviocytes from hemophilia A patients with
severe HA.
The findings that systemic levels of TNF-α were strongly increased and correlated with disease
severity in our patients indicate that this cytokine may be tightly related to the evolution of HA.
Indeed, we found significant associations between circulating levels of TNF-α and multiple clinical
parameters of HA, including the number of hemarthroses, the grade of synovial hypertrophy, and the
clinical WFH score and US score, which altogether suggest a role for TNF-α in the progression of
blood-induced arthropathy and its possible suitability in the future as a biomarker of disease severity
that could potentially be used to identify patients with progressing joint disease. Moreover, our
observation that local synovial expression of TNF-α, TNF-R1, and TNF-R2 is robustly increased in
HA and retained in vitro by cultured HA fibroblast-like synoviocytes provides strong support to the
notion that TNF-α/TNF-R signaling may be dysregulated in hemophiliacs as previously reported in
hemophilic FVIII-deficient mice [19]. This assumption is further corroborated by our in vitro findings
obtained through functional assays and demonstrating that, at variance with OA control fibroblast-like
synoviocytes, HA fibroblast-like synoviocytes are strongly responsive to the stimulation with TNF-α.
Considering that the TNF-α/TNF-R system may activate a multitude of intracellular signaling pathways
resulting in the promotion of either cell survival/proliferation or apoptosis in different contexts [30,31],
we tested the possible effects of TNF-α challenge on both cellular activities. Hence, we found that TNF-α
is capable of greatly fostering the proliferation of HA fibroblast-like synoviocytes, while it did not
promote cell death signals as testified by unchanged levels of active/cleaved caspase-3 compared with
resting cells. Taken together, our findings support the concept that TNF-α may represent an important
mediator of proliferative synovitis in patients with severe HA. Interestingly, this evidence further
supports that HA may share important cellular and molecular pathomechanisms with RA [4,8,29], as it
is well known that TNF-α induces sustained signaling and a prolonged and unremitting inflammatory
response in RA synovial fibroblasts which orchestrates pannus formation and subsequent articular
cartilage invasion and destruction [32].
Consistent with recent observations in a mouse model for HA [19], the data from HA patients
presented herein open a new scenario putting the proinflammatory TNF-α pathway among those worth
to be targeted for therapeutic purposes. The feasibility of TNF-α antagonism as a novel strategy to treat
HA clearly deserves a thorough investigation, especially if considering that, over the last two decades,
anti-TNF-α biologics became the most powerful tools for controlling patients suffering from a number
of rheumatic diseases, such as RA, psoriatic arthritis, and ankylosing spondylitis, with sustained
efficacy and acceptable safety profiles as demonstrated in long-term follow-up studies [16,33,34].
In a small case series of hemophilia A patients with overlapping RA or psoriatic arthritis, systemic
anti-TNF-α therapy with adalimumab proved to be useful not only in controlling synovitis and
inducing disease remission but also in reducing joint bleeding [35]. Of note, through careful infectious
screening and serological monitoring, anti-TNF-α therapy could be safely used even in hemophiliacs
presenting viral infections, which are usually considered a major contraindication for this kind of
treatment [35]. Furthermore, in hemophilic mice subjected to intra-articular bleeding, treatment with
etanercept to block TNF-α reduced synovial inflammation and largely prevented the activation of
osteoclasts and the resulting osteopenia in the trabecular bone adjacent to the hemarthrosis [19]. It is
worth noting that the lack of osteopenia in the contralateral uninjured joint led the authors to propose
that, in this mouse model of HA, the release of TNF-α from the hemarthrosis acts locally and not
systemically, which might suggest the use of an intra-articular anti-TNF-α biologic administration [19].
However, the clinical evidence that HA may often affect multiple joints in the same patient and our
current observation that circulating TNF-α is strongly increased and correlated with HA severity in
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hemophilia A patients might, instead, be in favor of a systemic anti-TNF-α therapeutic approach.
Indeed, the significant relationship between serum levels of TNF-α and the number of hemarthroses
in our patients supports the concept that joint bleeds, especially repetitive bleeds, might promote a
systemic proinflammatory state.
Although our novel findings highlight a non-negligible participation of the TNF-α/TNF-R system
to the pathobiology of human HA, we are aware that further in-depth molecular studies will be
required to better decipher the mechanisms of action of this pleiotropic pathway and to identify
potential downstream therapeutic targets. In fact, it is well known that TNF-α activates complex
signaling cascades and induces many other proinflammatory mediators, such as IL-6, whose signaling
is currently attracting much attention as a target for the treatment of chronic arthritis and, possibly, also
to protect against HA [36–39]. Whether abnormal iRhom2/ADAM17-dependent membrane-anchored
TNF-α precursor shedding from macrophages might be primarily responsible for the increased levels
of TNF-α in HA patients, as demonstrated in hemophilic mice [19], also remains to be determined.
Although a previous important study reported that TNF-α is not pivotal in blood-induced cartilage
damage [40], our in vitro data suggest an important role for this cytokine at least in the induction
of HA fibroblast-like synoviocyte proliferation and synovial hyperplasia, and further investigations
are necessary to elucidate its possible participation in additional pathomechanisms of HA, such as
neoangiogenesis [41,42]. Finally, in line with recent findings suggesting that HA in hemophilia B
may be less severe than in hemophilia A as reflected by either clinical parameters or differences in
levels of TNF/TNF-R superfamily members controlling bone turnover, such as osteoprotegerin and
activator of nuclear factor-kB ligand [8,26], it will be of major importance to also search for possible
differences in the proinflammatory TNF-α pathway between the two types of hemophilia. Owing to
the cross-sectional design of our study, we consider that further prospective investigations in larger
patient cohorts will be necessary to shed light on the potential of the TNF-α pathway as a biomarker
reflecting HA evolution.
In summary, our results add to recent data on murine HA [19] and provide new insights into
the role of the TNF-α/TNF-R system in blood-induced proliferative synovitis, thereby strengthening
the notion that this pathway might represent a new target for the prevention and treatment of joint
damage in HA patients. Indeed, at present HA remains the largest cause of morbidity in patients with
hemophilia despite advancements in factor replacement therapy and new developments in innovative
therapeutic approaches [8–10]. Especially when considering that factor replacement alone may be not
sufficient in advanced HA, we believe that our findings provide the groundwork for further clinical
investigation of anti-TNF-α therapeutic feasibility in hemophiliacs.
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